New Insights into the Mechanisms of Immunotherapy

Overview

Journal Eur Arch Otorhinolaryngol

Specialty Otorhinolaryngology

Date 1995 Jan 1

PMID 7734977

Authors

S R Durham

Affiliations

Soon will be listed here.

Abstract

Allergen-specific immunotherapy retains a place in treatment in patients with allergic rhinitis who fail to respond to conventional treatment with antihistamines and topical corticosteroids. Studies on mechanisms of immunotherapy have previously focussed on changes in serum antibodies, including blunting of seasonal rises in specific IgE and increase in "blocking" specific IgG antibodies. Immunotherapy in patients with rhinitis has also been shown to inhibit effector cells with a decrease in nasal mucosal eosinophils and epithelial mast cells. Recent evidence suggests that these events may be orchestrated by an effect of immunotherapy on T lymphocytes with alteration from a predominant "Th2" response (interleukin 4 and 5) in favour of an additional "Th1" response (gamma interferon) which may decrease tissue eosinophilia and local IgE production. Novel therapeutic approaches to allergic diseases might include use of topical gamma interferon, immunosuppressive agents, anti-CD4 antibodies or strategies directed specifically against IL-4 or IL-5.

References

. CSM Update: Desensitising vaccines. Br Med J (Clin Res Ed). 2010; 293(6552):948. PMC: 1341725. View

OHehir R, Yssel H, Verma S, De Vries J, Spits H, Lamb J . Clonal analysis of differential lymphokine production in peptide and superantigen induced T cell anergy. Int Immunol. 1991; 3(8):819-26. DOI: 10.1093/intimm/3.8.819. View

Van Bever H, Stevens W . Suppression of the late asthmatic reaction by hyposensitization in asthmatic children allergic to house dust mite (Dermatophagoides pteronyssinus). Clin Exp Allergy. 1989; 19(4):399-404. DOI: 10.1111/j.1365-2222.1989.tb02405.x. View

Varney V, Hamid Q, Gaga M, Ying S, Jacobson M, Frew A . Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest. 1993; 92(2):644-51. PMC: 294897. DOI: 10.1172/JCI116633. View

Furin M, Norman P, Creticos P, Proud D, Lichtenstein L, Naclerio R . Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity. J Allergy Clin Immunol. 1991; 88(1):27-32. DOI: 10.1016/0091-6749(91)90297-2. View

Lichtenstein L, Ishizaka K, Norman P, Sobotka A, Hill B . IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy. J Clin Invest. 1973; 52(2):472-82. PMC: 302277. DOI: 10.1172/JCI107204. View

Frew A, Kay A . The relationship between infiltrating CD4+ lymphocytes, activated eosinophils, and the magnitude of the allergen-induced late phase cutaneous reaction in man. J Immunol. 1988; 141(12):4158-64. View

Rak S, Lowhagen O, Venge P . The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen-allergic patients. J Allergy Clin Immunol. 1988; 82(3 Pt 1):470-80. DOI: 10.1016/0091-6749(88)90021-8. View

Kay A, Ying S, Varney V, Gaga M, Durham S, Moqbel R . Messenger RNA expression of the cytokine gene cluster, interleukin 3 (IL-3), IL-4, IL-5, and granulocyte/macrophage colony-stimulating factor, in allergen-induced late-phase cutaneous reactions in atopic subjects. J Exp Med. 1991; 173(3):775-8. PMC: 2118805. DOI: 10.1084/jem.173.3.775. View

10.

Varney V, Jacobson M, Sudderick R, Robinson D, Irani A, Schwartz L . Immunohistology of the nasal mucosa following allergen-induced rhinitis. Identification of activated T lymphocytes, eosinophils, and neutrophils. Am Rev Respir Dis. 1992; 146(1):170-6. DOI: 10.1164/ajrccm/146.1.170. View

11.

Pienkowski M, Norman P, Lichtenstein L . Suppression of late-phase skin reactions by immunotherapy with ragweed extract. J Allergy Clin Immunol. 1985; 76(5):729-34. DOI: 10.1016/0091-6749(85)90679-7. View

12.

Varney V, Gaga M, Frew A, Aber V, Kay A, Durham S . Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ. 1991; 302(6771):265-9. PMC: 1668945. DOI: 10.1136/bmj.302.6771.265. View

13.

Otsuka H, Mezawa A, Ohnishi M, Okubo K, Seki H, Okuda M . Changes in nasal metachromatic cells during allergen immunotherapy. Clin Exp Allergy. 1991; 21(1):115-9. DOI: 10.1111/j.1365-2222.1991.tb00812.x. View

14.

Kemeny D, Tomioka H, Tsutsumi A, Koike T, Lessof M, Lee T . The relationship between anti-IgE auto-antibodies and the IgE response to wasp venom during immunotherapy. Clin Exp Allergy. 1990; 20(1):67-9. DOI: 10.1111/j.1365-2222.1990.tb02777.x. View

15.

Warner J, Price J, Soothill J, Hey E . Controlled trial of hyposensitisation to Dermatophagoides pteronyssinus in children with asthma. Lancet. 1978; 2(8096):912-5. DOI: 10.1016/s0140-6736(78)91630-6. View

16.

Chapman M . Use of nonstimulatory peptides: a new strategy for immunotherapy?. J Allergy Clin Immunol. 1991; 88(3 Pt 1):300-2. DOI: 10.1016/0091-6749(91)90091-2. View

17.

Rocklin R, Sheffer A, Greineder D, Melmon K . Generation of antigen-specific suppressor cells during allergy desensitization. N Engl J Med. 1980; 302(22):1213-9. DOI: 10.1056/NEJM198005293022201. View

18.

Bousquet J, Hejjaoui A, Soussana M, Michel F . Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. IV. Comparison of the safety and efficacy of two dosages of a high-molecular-weight allergoid. J Allergy Clin Immunol. 1990; 85(2):490-7. DOI: 10.1016/0091-6749(90)90160-6. View

19.

Durham S, Varney V, Gaga M, Frew A, Jacobson M, Kay A . Immunotherapy and allergic inflammation. Clin Exp Allergy. 1991; 21 Suppl 1:206-10. DOI: 10.1111/j.1365-2222.1991.tb01729.x. View

20.

Ying S, Durham S, Barkans J, Masuyama K, Jacobson M, Rak S . T cells are the principal source of interleukin-5 mRNA in allergen-induced rhinitis. Am J Respir Cell Mol Biol. 1993; 9(4):356-60. DOI: 10.1165/ajrcmb/9.4.356. View